Animalcare Group PLC Trading Update & Notice of Results (6523A)
23 Enero 2020 - 1:00AM
UK Regulatory
TIDMANCR
RNS Number : 6523A
Animalcare Group PLC
23 January 2020
23 January 2020
Animalcare Group plc
(the "Group" or the "Company")
Trading Update & Notice of Results
23 January 2020. Animalcare Group plc (AIM: ANCR), the
international animal health business, today provides the following
unaudited trading update in advance of its full year results for
the financial year ended 31 December 2019 (the "Year"), which are
scheduled to be announced on 31 March 2020.
Highlights:
-- Earnings in line with market expectations
-- Significant improvement in cash conversion versus the prior year
-- Strong net debt reduction of over 30% YoY
-- Launched Procanicare post period end in January 2020
Trading overview
Earnings for the Group for the period to 31 December 2019 were
in line with market expectations. The Group's focus on building a
strong platform for driving the future growth of the business has
been demonstrated by the improvement in all our strategic KPIs and
our developing portfolio of new product opportunities.
Revenue for the year to 31 December 2019 was GBP71.1m (2018:
GBP72.5m) a decline of 1.5% (c1.0% at constant exchange rate).
Whilst new product launches accounted for GBP1.8m additional sales,
revenue was impacted by the previously reported supply challenges
by GBP1.7m and the decline in use of antibiotics in production
animals of GBP1m, as expected.
The Company committed to improving its cash performance and
reducing net debt during 2019. In line with these objectives, the
Company expects to have significantly improved its underlying cash
conversion versus the 80% achieved in 2018. Net debt (excluding
IFRS16 lease liabilities of cGBP1.8m) was around GBP15.9m as at 31
December 2019 (31 December 2018: GBP23.6m), the reduction largely
driven by the higher cash conversion noted above and targeted
capital expenditure.
Strategic progress
The Group continues to execute upon its strategic priorities to
deliver sustainable, profitable growth.
Product portfolio
-- Resources focused on the promotion of sustainable and higher
margin products. Around 25% of product brands are being delisted or
divested, with no significant impact to profit
Pipeline
-- Four new products launched over 2019 - Cortacare, Butazocare, Doxycare and Metrocare
-- Planned regulatory approval for one new product and
submission of a novel pain product during Q1 2020
Business development
-- Signed an exclusive agreement with American Regent Animal
Health to relaunch Adequan in Europe. Relaunch is subject to
regulatory approval
-- Signed a new distribution agreement for Procanicare, the
first product to be launched across all of the Group's seven
territories. The product was launched in January 2020, post period
end
Animalcare's Chief Executive Officer, Jenny Winter, commented:
"We have made strong progress over the last twelve months
delivering our five-pillar strategy alongside the continued drive
towards greater integration, simplification and efficiency. This is
reflected in our improving cash position and strengthening
financial measures, despite the impact of the external
manufacturing and supply issues we faced throughout 2019. We will
continue to focus over 2020 on further building out the platform to
strengthen the long-term growth and sustainability of our
business."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
For further information, please contact:
Animalcare Group plc Tel: 01904 487 687
Jenny Winter, Chief Executive
Officer
Chris Brewster, Chief Financial
Officer
Panmure Gordon (Nominated Adviser Tel: 020 7886 2500
& Broker)
Corporate Finance
Freddy Crossley / Emma Earl
Corporate Broking
James Stearns
animalcare@consilium-comms.com
Consilium Strategic Communications
Amber Fennell/Angela Gray/Olivia
Manser
About Animalcare (www.animalcaregroup.com)
Animalcare Group plc is a UK AIM listed veterinary sales and
marketing organisation, operating in seven countries and exports to
approximately 32 countries in Europe and a further 16 worldwide.
The company is focused on bringing new and innovative products to
market through its own development pipeline, partnerships and via
acquisition.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFLFITLTIFFII
(END) Dow Jones Newswires
January 23, 2020 02:00 ET (07:00 GMT)
Animalcare (AQSE:ANCR.GB)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Animalcare (AQSE:ANCR.GB)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025